Scribe Therapeutics launches first gene‑editing IPO in over two years, targeting high‑cholesterol gene
Scribe Therapeutics, a gene‑editing biotech based in California, announced its initial public offering, the first for a CRISPR‑focused company in more than two years.
The company, founded by researchers from UC Berkeley, aims to make CRISPR‑based medicines more scalable and accessible, focusing on cardiovascular diseases that affect millions.
Its lead program seeks to temporarily switch off a gene linked to high cholesterol rather than permanently edit the genome, a strategy the CEO says could improve safety.
The IPO was priced and filed while the firm occupies renovated buildings on the historic Alameda Works Shipyard site, symbolizing a shift from shipbuilding to cutting‑edge gene therapy.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that